Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea flag South Korea · Delayed Price · Currency is KRW
93,400
0.00 (0.00%)
At close: Feb 11, 2026

KRX:185750 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
1,680,9881,586,4311,669,4041,488,3451,343,5591,303,006
Other Revenue
--0----
1,680,9881,586,4311,669,4041,488,3451,343,5591,303,006
Revenue Growth (YoY)
0.32%-4.97%12.16%10.78%3.11%20.72%
Cost of Revenue
1,154,5471,053,8201,007,203945,705847,741813,866
Gross Profit
526,441532,611662,202542,639495,818489,140
Selling, General & Admin
274,667267,793256,595237,936220,982202,292
Research & Development
165,741143,914140,235176,325163,277146,664
Amortization of Goodwill & Intangibles
3,8923,0802,1691,9261,7941,982
Other Operating Expenses
12,46712,60511,69411,38712,20610,184
Operating Expenses
462,593433,150415,602432,733401,060365,204
Operating Income
63,84899,462246,599109,90694,759123,936
Interest Expense
-7,012-8,319-9,271-6,847-4,030-3,871
Interest & Investment Income
8,37412,6916,0282,333759.371,387
Earnings From Equity Investments
--798.36-460.38-603.47-
Currency Exchange Gain (Loss)
-1,3152,918-2,356-2,524-183.41-569.56
Other Non Operating Income (Expenses)
-108.34-1,208-1,777838.33-10,128371.38
EBT Excluding Unusual Items
63,787105,543240,021103,24680,573121,253
Gain (Loss) on Sale of Investments
-3,514-2,7641,465-2,223-98.87517.38
Gain (Loss) on Sale of Assets
59.44154111.8854.05119.3468.18
Asset Writedown
-56.24-923.8--3,912--
Pretax Income
60,277102,009241,59897,16580,594121,839
Income Tax Expense
675.97-9,43327,99617,18738,23731,434
Earnings From Continuing Operations
59,601111,442213,60279,97842,35690,405
Minority Interest in Earnings
-358.27-2,369-1,081975.58363.911,228
Net Income
59,242109,073212,52180,95342,72091,633
Net Income to Common
59,242109,073212,52180,95342,72091,633
Net Income Growth
-68.66%-48.68%162.52%89.50%-53.38%70.06%
Shares Outstanding (Basic)
131314131414
Shares Outstanding (Diluted)
131314131414
Shares Change (YoY)
-5.39%-5.20%3.79%-1.77%-0.73%-0.06%
EPS (Basic)
4500.588234.4615210.376013.653117.386637.55
EPS (Diluted)
4500.588234.4615210.376013.653117.386637.55
EPS Growth
-66.88%-45.86%152.93%92.91%-53.03%70.17%
Free Cash Flow
-123,89425,815276,94222,836-35,33971,684
Free Cash Flow Per Share
-9412.081948.9119821.041696.38-2578.755192.55
Dividend Per Share
1100.0001100.000----
Gross Margin
31.32%33.57%39.67%36.46%36.90%37.54%
Operating Margin
3.80%6.27%14.77%7.38%7.05%9.51%
Profit Margin
3.52%6.88%12.73%5.44%3.18%7.03%
Free Cash Flow Margin
-7.37%1.63%16.59%1.53%-2.63%5.50%
EBITDA
107,713139,234283,629143,504122,241147,721
EBITDA Margin
6.41%8.78%16.99%9.64%9.10%11.34%
D&A For EBITDA
43,86439,77237,03033,59827,48223,786
EBIT
63,84899,462246,599109,90694,759123,936
EBIT Margin
3.80%6.27%14.77%7.38%7.05%9.51%
Effective Tax Rate
1.12%-11.59%17.69%47.45%25.80%
Advertising Expenses
-74,74069,70760,36451,32945,629
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.